Usually only if you have type 2 diabetes. Mounjaro (tirzepatide) is FDA-approved to improve blood sugar control in type 2 diabetes, and to lower the risk of heart attack, stroke and cardiovascular death in adults with type 2 diabetes at high risk of them. It has no weight-loss approval, and insurers’ coverage rules follow the approval. If you want tirzepatide for weight management, the product your plan will look at is Zepbound, which contains the same medicine and is approved for weight.
Here is what plans actually ask for, how Medicare handles it, and what to do if the answer is no.
Why the diagnosis decides coverage
Mounjaro’s label lists two uses, and both require type 2 diabetes: blood sugar control in adults and children 10 and older, and cardiovascular risk reduction in adults with type 2 diabetes who are at high risk. Zepbound, the same active ingredient from the same maker, is approved to reduce and keep off excess weight in adults with obesity, or with overweight plus a weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.
Plans write their rules around those approvals. Two current examples:
- UnitedHealthcare (commercial prior-authorization policy, effective July 1, 2026) says Mounjaro and similar drugs “are only indicated for the treatment of type 2 DM and are not FDA approved for the treatment of weight loss.” It asks for medical records confirming type 2 diabetes with a qualifying lab value, and notes that “medications used for the purposes of weight loss are typically excluded from benefit coverage” (UnitedHealthcare policy).
- Mass General Brigham Health Plan (effective September 1, 2026) says its diabetes GLP-1s “will not be approved for non-FDA-approved indications (e.g., weight management, prediabetes, type 1 diabetes)” (Mass General Brigham Health Plan policy).
Your own plan’s rules may differ, but this is the common shape: a diabetes diagnosis documented in your records, often with lab results, before Mounjaro is approved. A prescription has to match your actual diagnosis; asking a doctor to code it any other way is not an option.
If you have type 2 diabetes
Plans that cover Mounjaro for type 2 diabetes often require prior authorization first, as UnitedHealthcare’s policy above does. Ask your plan for its formulary tier and prior-authorization criteria, and have your doctor submit your diagnosis and lab results with the request.
If your commercial plan covers it, Lilly’s savings card can bring a fill down to as little as $25, with savings capped at $150 a month and $1,950 a year. The card requires commercial insurance and a prescription for an FDA-approved use, excludes anyone on Medicare, Medicaid or other government coverage, and ends December 31, 2026 (Mounjaro savings terms). What the card does when your plan does not cover Mounjaro is covered in how much Mounjaro costs without insurance.
If you want it for weight loss
Expect a Mounjaro request for weight alone to be denied. The more useful questions for your plan are:
- Does my plan cover Zepbound, or any medicine for weight management? Some plans exclude weight-loss drugs as a category (UnitedHealthcare’s policy says they are “typically excluded”); others cover them with criteria. Does insurance cover Zepbound? walks through that request and what to do after a denial.
- Do I have a condition that is covered? Zepbound is approved for moderate to severe obstructive sleep apnea in adults with obesity, and coverage rules can treat that differently from weight loss: Medicare Part D, for example, can cover GLP-1s for sleep apnea but not for weight loss.
- What exactly was denied, and why? A denial for missing records is not the same as an exclusion. Ask for the written reason before deciding what to do next.
Medicare and Medicaid
Medicare Part D cannot cover drugs used for weight loss: the Part D manual excludes “agents when used for anorexia, weight loss, or weight gain” (CMS, Part D manual chapter 6). For type 2 diabetes it is different, and Lilly says Mounjaro is covered on many Part D plans for that use; check your own plan’s formulary.
Since July 1, 2026, a temporary program called the Medicare GLP-1 Bridge has covered some GLP-1s for weight management with a $50 monthly copay, through December 31, 2027. Mounjaro is not one of them: the Bridge covers Foundayo, Wegovy (injection and tablets) and the Zepbound KwikPen (CMS). People with type 2 diabetes are not eligible for the Bridge, because their GLP-1 coverage runs through ordinary Part D (Medicare.gov).
Medicaid programs must cover GLP-1s for medically accepted uses such as type 2 diabetes. Covering them for obesity is optional, and KFF counted 13 state programs doing so under fee-for-service as of January 2026 (KFF). Ask your state program or managed-care plan directly.
Where Gentle Health fits
We don’t prescribe Mounjaro. For weight management, our doctor prescribes brand-name Zepbound, the same medicine approved for weight, in all 41 jurisdictions where our physician is licensed. You pay us $28/month for the doctor’s care and buy the Zepbound vials or KwikPen from LillyDirect at its self-pay price, $299 to $449 a month by dose as of October 18, 2026. There is no minimum, and you can cancel any time.
We also prescribe compounded tirzepatide and compounded semaglutide as weekly injections. We do not bill insurance, so no plan approval is involved and the price is the same with or without coverage: tirzepatide starts at $169 a month and semaglutide at $135, with the medication, physician care, visits, messaging and overnight refrigerated shipping included. HSA and FSA cards are accepted.
Compounded medications are not FDA-approved, and compounded tirzepatide is not a generic or an equivalent version of Mounjaro or Zepbound. If your plan covers an FDA-approved option, that route may cost you less, and it is worth checking first. If it does not, what to do when insurance will not cover weight-loss medication lays out the options.
Frequently asked questions
Will insurance cover Mounjaro for weight loss? Usually not. Mounjaro is approved only for uses that involve type 2 diabetes, and plans such as UnitedHealthcare require records confirming that diagnosis. For weight management, ask your plan about Zepbound, which contains the same medicine and is approved for weight. If your plan won’t cover it, our doctor can prescribe Zepbound for self-pay through LillyDirect.
Is Mounjaro the same as Zepbound? Both contain tirzepatide and are made by Eli Lilly. Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight management and for obstructive sleep apnea in adults with obesity. Insurers treat them as different products.
Does Medicare cover Mounjaro? Many Part D plans cover it for type 2 diabetes. Medicare cannot cover it for weight loss, and it is not one of the drugs in the Medicare GLP-1 Bridge.
Can I use the Mounjaro savings card on Medicare? No. Lilly’s card excludes anyone enrolled in Medicare, Medicaid or other government healthcare programs.
What if my plan denies Mounjaro? Get the written reason first. A denial for missing records or labs can be fixed with documentation; an exclusion for weight-loss use cannot. Then ask whether Zepbound or another weight-management option is covered.
Dr. James Simmons, MD